HSD17B12

Across TCGA pan-cancer cohorts, HSD17B12 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSD17B12 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HSD17B12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSD17B12 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and ESCA are the cancer types where HSD17B12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.162	0.697	<.001	51	view →
UCEC	DFS	Median	II,III,IV	1.000	0.308	.020	12	view →
ESCA	OS	Median	III,IV	0.130	0.574	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HSD17B12–HNSC (DFS)

Open the HNSC breakdown →